Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor
Dan You, Stephen Hillerman, Gregory Locke, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 1, pp. e001402-e001402
Open Access | Times Cited: 61

Showing 1-25 of 61 citing articles:

The expanding role for small molecules in immuno-oncology
Rienk Offringa, Lisa Kötzner, Bayard R. Huck, et al.
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 11, pp. 821-840
Closed Access | Times Cited: 86
Next generations of CAR-T cells - new therapeutic opportunities in hematology?
Jaromir Tomasik, Marcin Jasiński, Grzegorz Basak
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 85
Role of protein phosphorylation in cell signaling, disease, and the intervention therapy
Kun Pang, Wei Wang, Jiaxin Qin, et al.
MedComm (2022) Vol. 3, Iss. 4
Open Access | Times Cited: 64
Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways
Zhi Zhu, A. J. Robert McGray, Weijian Jiang, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 58
Strategies to overcome DC dysregulation in the tumor microenvironment
Guillaume Mestrallet, Kazuki Sone, Nina Bhardwaj
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 39
Current strategies for targeting HPK1 in cancer and the barriers to preclinical progress
Hui Chen, Xiangna Guan, Chi He, et al.
Expert Opinion on Therapeutic Targets (2024) Vol. 28, Iss. 4, pp. 237-250
Closed Access | Times Cited: 8
Hematopoietic Progenitor Kinase 1 in Tumor Immunology: A Medicinal Chemistry Perspective
Qiangsheng Zhu, Nannan Chen, Xinjian Tian, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 12, pp. 8065-8090
Closed Access | Times Cited: 34
The development of small-molecule inhibitors targeting HPK1
Lixin Zhou, Tianyu Wang, Kuojun Zhang, et al.
European Journal of Medicinal Chemistry (2022) Vol. 244, pp. 114819-114819
Closed Access | Times Cited: 33
Discovery of novel, potent, selective and orally bioavailable HPK1 inhibitor for enhancing the efficacy of anti-PD-L1 antibody
Shenxin Zeng, Mingfei Wu, Yuyuan Jin, et al.
European Journal of Medicinal Chemistry (2024) Vol. 267, pp. 116206-116206
Closed Access | Times Cited: 6
Discovery of Orally Active Isofuranones as Potent, Selective Inhibitors of Hematopoetic Progenitor Kinase 1
Andrew P. Degnan, Godwin Kumi, Christopher W. Allard, et al.
ACS Medicinal Chemistry Letters (2021) Vol. 12, Iss. 3, pp. 443-450
Open Access | Times Cited: 37
Inhibitors of immuno-oncology target HPK1 – a patent review (2016 to 2020)
Ian D. Linney, Neelu Kaila
Expert Opinion on Therapeutic Patents (2021) Vol. 31, Iss. 10, pp. 893-910
Closed Access | Times Cited: 33
Therapeutic effects of ginseng and ginsenosides on colorectal cancer
Linxian Zhao, Yueming Zhang, Yajuan Li, et al.
Food & Function (2022) Vol. 13, Iss. 12, pp. 6450-6466
Closed Access | Times Cited: 26
Small Molecule Targeting Immune Cells: A Novel Approach for Cancer Treatment
Shilpi Singh, Debashis Barik, Ananta Prasad Arukha, et al.
Biomedicines (2023) Vol. 11, Iss. 10, pp. 2621-2621
Open Access | Times Cited: 14
Multi-layered effects of Panax notoginseng on immune system
Chunhao Yang, Liping Qu, Rui Wang, et al.
Pharmacological Research (2024) Vol. 204, pp. 107203-107203
Open Access | Times Cited: 5
HPK1 Dysregulation‐Associated NK Cell Dysfunction and Defective Expansion Promotes Metastatic Melanoma Progression
Woo Seon Choi, Hyung‐Joon Kwon, Eunbi Yi, et al.
Advanced Science (2024) Vol. 11, Iss. 29
Open Access | Times Cited: 5
Discovery of Spiro-azaindoline Inhibitors of Hematopoietic Progenitor Kinase 1 (HPK1)
Bryan Chan, Eileen M. Seward, Michael Lainchbury, et al.
ACS Medicinal Chemistry Letters (2021) Vol. 13, Iss. 1, pp. 84-91
Open Access | Times Cited: 31
Anti-PD-1 combined with targeted therapy: Theory and practice in gastric and colorectal cancer
Yao Chen, Bingjun Bai, Kangkang Ying, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2022) Vol. 1877, Iss. 5, pp. 188775-188775
Closed Access | Times Cited: 22
Small molecule inhibitors for cancer immunotherapy and associated biomarkers – the current status
Lisa Schlicher, Luke G. Green, Andrea Romagnani, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
Highly potent, orally active novel small-molecule HPK1 inhibitor DS21150768 induces anti-tumor responses in multiple syngeneic tumor mouse models
Genzui Setsu, Megumi Goto, Kentaro Ito, et al.
European Journal of Pharmacology (2023) Vol. 961, pp. 176184-176184
Closed Access | Times Cited: 11
Design, Synthesis, and Pharmacological Evaluation of Isoindoline Analogues as New HPK1 Inhibitors
Cheng-Hu Xie, Bo Liu, Zilan Song, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 23, pp. 16201-16221
Closed Access | Times Cited: 11
Unraveling the Role of the NLRP3 Inflammasome in Lymphoma: Implications in Pathogenesis and Therapeutic Strategies
Ioanna Ε. Stergiou, C. Tsironis, Stavros P. Papadakos, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 4, pp. 2369-2369
Open Access | Times Cited: 4
Discovery of 5-aminopyrido[2,3-d]pyrimidin-7(8H)-one derivatives as new hematopoietic progenitor kinase 1 (HPK1) inhibitors
Xiaorong Qiu, Rong Liu, Huan Ling, et al.
European Journal of Medicinal Chemistry (2024) Vol. 269, pp. 116310-116310
Closed Access | Times Cited: 4
HPK1 citron homology domain regulates phosphorylation of SLP76 and modulates kinase domain interaction dynamics
Avantika S. Chitre, Ping Wu, Benjamin T. Walters, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 4
Design, Synthesis, and biological evaluation of 7H-Pyrrolo[2,3-d]pyrimidines as potent HPK1 kinase inhibitors
Feifei Wu, Huiyu Li, Weiqiang Li, et al.
Bioorganic & Medicinal Chemistry (2025) Vol. 119, pp. 118079-118079
Closed Access
Design, synthesis, and biological evaluation of 2,4-diaminopyrimidine inhibitors of hematopoietic progenitor kinase 1
Chunting Li, J. Liu, Luwen Ren, et al.
Bioorganic & Medicinal Chemistry Letters (2025), pp. 130242-130242
Closed Access
Page 1 - Next Page

Scroll to top